MedTrace Logo

SHOX2_PTGER4 DNA Methlyation in Lung Cancer

NCT04321499 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 70

Last updated 2020-03-25

No results posted yet for this study

Summary

Data on SHOX2 and PTGER4 DNA Methylation suggest possible use as a biomarker for early lung cancer diagnosis.

In this study a control group consisting of COPD patients with a CT-scan of the chest no older than 6 weeks and a control group of patients with a nodule and ruled out diagnosis of lung cancer will be included.

SHOX2 and PTGER4 will be analyzed via PCR.

Conditions

  • Lungcancer

Interventions

GENETIC

lung cancer

PCR for SHOX2 and PTGER4

Sponsors & Collaborators

  • University Hospital, Essen

    lead OTHER

Principal Investigators

  • Kaid Darwiche, MD · head of deparment of interventional pneumology, Ruhrlandklinik, UHEssen

Eligibility

Min Age
18 Years
Max Age
95 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-31
Primary Completion
2017-03-31
Completion
2017-03-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04321499 on ClinicalTrials.gov